Skip to main content
OpenTrials
Completed

NCT Number: NCT01034618

Protein Hydrolyzation and Glycemic Control

The insulinotropic effects of protein hydrolysate/amino acid ingestion have been shown to regulate blood glucose homeostasis in both type 2 diabetes patients and normoglycemic controls. The objective of the study is to investigate the optimal dose of such an insulinotropic mixture.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–70 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Maastricht University Medical Center+

Maastricht, Limburg, 6229ER, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male
  • Age between 40 and 70 years
  • Oral blood glucose lowering medication
  • BMI < 35 kg/m2

Exclusion criteria

  • Exogenous insulin use
  • Cardiac disease (any cardiac event in the last 5 years)
  • Diabetic complications (microvascular complications, microalbuminuria: albumin:creatinine ratio >2,5)

Treatment and study plan

Protein hydrolyzation

Dietary Supplement

Primary outcomes

  1. Glucose and insulin homeostasis.

Secondary outcomes

  1. Plasma amino acid profiles

Sponsors and collaborators

Lead sponsor

Maastricht University Medical Center

Other

Registry information

Official study title

The Additional Effects of Protein Hydrolysate Supplementation on Glucose Homeostasis in Type 2 Diabetes

Important dates

Study start
2007
Primary completion
2008
Study completion
2009
First posted
Dec 17, 2009
Registry last updated
Dec 17, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.